83 related articles for article (PubMed ID: 29792006)
21. Antisense RNA-regulated programmed cell death.
Gerdes K; Gultyaev AP; Franch T; Pedersen K; Mikkelsen ND
Annu Rev Genet; 1997; 31():1-31. PubMed ID: 9442888
[TBL] [Abstract][Full Text] [Related]
22. Revealing natural antisense transcripts from Plasmodium vivax isolates: evidence of genome regulation in complicated malaria.
Boopathi PA; Subudhi AK; Garg S; Middha S; Acharya J; Pakalapati D; Saxena V; Aiyaz M; Chand B; Mugasimangalam RC; Kochar SK; Sirohi P; Kochar DK; Das A
Infect Genet Evol; 2013 Dec; 20():428-43. PubMed ID: 24121022
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide characterization of human L1 antisense promoter-driven transcripts.
Criscione SW; Theodosakis N; Micevic G; Cornish TC; Burns KH; Neretti N; Rodić N
BMC Genomics; 2016 Jun; 17():463. PubMed ID: 27301971
[TBL] [Abstract][Full Text] [Related]
24. Processing of naturally occurring sense/antisense transcripts of the vertebrate Slc34a gene into short RNAs.
Carlile M; Nalbant P; Preston-Fayers K; McHaffie GS; Werner A
Physiol Genomics; 2008 Jun; 34(1):95-100. PubMed ID: 18413783
[TBL] [Abstract][Full Text] [Related]
25. Suppression of HUVEC tissue factor synthesis by antisense oligodeoxynucleotide.
Stephens AC; Ranlall NF; Rivers RP
Thromb Res; 2008; 122(1):99-107. PubMed ID: 17920661
[TBL] [Abstract][Full Text] [Related]
26. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation.
Shao Y; Wu Y; Chan CY; McDonough K; Ding Y
Nucleic Acids Res; 2006; 34(19):5660-9. PubMed ID: 17038332
[TBL] [Abstract][Full Text] [Related]
27. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
28. [Synthesis and cloning of genes for the antisense peptides for human calcitonin and miniproinsulin].
Efimov VA; Aronova EA; Buriakova AA; Kalinkina AL; Letunova AB; Fradkov AF; Chakhmakhcheva OG
Bioorg Khim; 1994 Jul; 20(7):759-71. PubMed ID: 7993380
[TBL] [Abstract][Full Text] [Related]
29. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
30. [Antisense targeting in neurology].
Tellería-Díaz A
Rev Neurol; 2000 Oct 16-31; 31(8):762-9. PubMed ID: 11082887
[TBL] [Abstract][Full Text] [Related]
31. Interplay of polyethyleneimine molecular weight and oligonucleotide backbone chemistry in the dynamics of antisense activity.
Sundaram S; Lee LK; Roth CM
Nucleic Acids Res; 2007; 35(13):4396-408. PubMed ID: 17576672
[TBL] [Abstract][Full Text] [Related]
32. Antisense RNA control in bacteria, phages, and plasmids.
Wagner EG; Simons RW
Annu Rev Microbiol; 1994; 48():713-42. PubMed ID: 7826024
[TBL] [Abstract][Full Text] [Related]
33. [An application of molecular cell biology to visualize and manipulate gene expressions of specific proteins in the neuroendocrine and pituitary systems].
Kawata M; Ueda S
Nihon Rinsho; 1993 Oct; 51(10):2530-5. PubMed ID: 8254917
[TBL] [Abstract][Full Text] [Related]
34. Recombinase-based reporter system and antisense technology to study gene expression and essentiality in hypoxic nonreplicating mycobacteria.
Rao SP; Camacho L; Huat Tan B; Boon C; Russel DG; Dick T; Pethe K
FEMS Microbiol Lett; 2008 Jul; 284(1):68-75. PubMed ID: 18544099
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of antisense therapeutic agents : cancer and inflamination.
Bennett CF; Dean N; Ecker DJ; Monia BP
Methods Mol Med; 1996; 1():13-46. PubMed ID: 21359715
[TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Ananta JS; Paulmurugan R; Massoud TF
Mol Pharm; 2015 Dec; 12(12):4509-17. PubMed ID: 26559642
[TBL] [Abstract][Full Text] [Related]
38. Telomerase RNA inhibition using antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate.
Kondo Y; Kondo S
Methods Mol Biol; 2007; 405():97-112. PubMed ID: 18369820
[TBL] [Abstract][Full Text] [Related]
39. PNA-based artificial nucleases as antisense and anti-miRNA oligonucleotide agents.
Gaglione M; Milano G; Chambery A; Moggio L; Romanelli A; Messere A
Mol Biosyst; 2011 Aug; 7(8):2490-9. PubMed ID: 21623442
[TBL] [Abstract][Full Text] [Related]
40. Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides.
Roth CM
Biophys J; 2005 Oct; 89(4):2286-95. PubMed ID: 16055530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
